We are proposing to enter into a new supply agreement with Novartis which would involve the funding of two new treatments for cancer, ribociclib (branded as Kisqali), for the treatment of people with HR-positive, HER2-negative locally advanced or metastatic breast cancer, and midostaurin (branded as Rydapt) for the treatment of people with acute myeloid leukaemia (AML) with a specific gene mutation known as a FLT3 mutation. The proposal would also result in the reduction of the net price of treatment for a currently funded heart failure medicine, sacubitril with valsartan (branded as Entresto) which would reduce via a confidential rebate. We would like to hear from people about this proposal which would give New Zealanders access to more cancer treatments.
Please follow this link to the consultation on our website for the full details.
Please share this information
We want to make sure everyone who might be interested is aware of these proposed changes. Please share this information with people you think might want to provide feedback on this consultation.
Conal Edwards | Senior Therapeutic Group Manager
Te Pātaka Whaioranga | Pharmac | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington | P: 0800 660 050 | https://smex12-5-en-ctp.trendmicro.com:443/wis/clicktime/v1/query?url=www.pharmac.govt.nz&umid=7576ab95-b0b8-474c-8716-acc1722b5b4a&auth=7d2d0abb068e5711621b1d94b8fe61c48225f872-ee21ab1a8b542a3f1617dd0e619ddbd2fef59024